Showing results (11-20 of 114) with videos related to
Sort By:
Pageof 12
The Biochemical Journal|February 28, 2012
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advancesLomon So, David A FrumanCancer Discovery|May 16, 2012
PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinicDavid A Fruman, Christian RommelNature Reviews. Drug Discovery|February 1, 2014
PI3K and cancer: lessons, challenges and opportunitiesDavid A Fruman, Christian RommelTrends in Immunology|July 16, 2003
Regulation of quiescence in lymphocytesIsharat Yusuf, David A FrumanTrends in Cancer|December 28, 2020
Targeting the Mevalonate Pathway in CancerDennis Juarez, David A FrumanTrends in Pharmacological Sciences|August 8, 2023
The road less traveled: activating an oncogenic kinaseMadhuri Paul, David A FrumanCurrent Topics in Microbiology and Immunology|June 22, 2010
PI3Ks in lymphocyte signaling and developmentKlaus Okkenhaug, David A FrumanClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2010
Target of rapamycin signaling in leukemia and lymphomaCollin Vu, David A FrumanAutoimmunity|August 31, 2007
Role of phosphoinositide 3-kinase signaling in autoimmunityJean S Oak, David A FrumanAnnals of the New York Academy of Sciences|April 5, 2013
Achieving cancer cell death with PI3K/mTOR-targeted therapiesSung Su Yea, David A FrumanPageof 12